Exercise increases serum
opioid levels and improves cardiovascular health. Here we tested the hypothesis that
opioids contribute to the acute cardioprotective effects of exercise using a rat model of exercise-induced cardioprotection. For the standard protocol, rats were randomized to 4 days of treadmill training and 1 day of vigorous exercise (day 5), or to a
sham exercise control group. On day 6, animals were killed, and global myocardial ischemic tolerance was assessed on a modified Langendorff apparatus. Twenty minutes of
ischemia followed by 3 h of reperfusion resulted in a mean
infarct size of 42 +/- 4% in hearts from
sham exercise controls and 21 +/- 3% (P < 0.001) in the exercised group. The cardioprotective effects of exercise were gone by 5 days after the final exercise period. To determine the role of
opioid receptors in exercise-induced cardioprotection, rats were exercised according to the standard protocol; however, just before exercise on days 4 and 5, rats were injected subcutaneously with 10 mg/kg of the
opioid receptor antagonist naltrexone. Similar
injections were performed in the
sham exercise control group.
Naltrexone had no significant effect on baseline myocardial ischemic tolerance in controls (
infarct size 43 +/- 4%). In contrast,
naltrexone treatment completely blocked the cardioprotective effect of exercise (
infarct size 40 +/- 5%). Exercise was also associated with an early increase in myocardial
mRNA levels for several
opioid system genes and with sustained changes in a number of genes that regulate
inflammation and apoptosis. These findings demonstrate that the acute cardioprotective effects of exercise are mediated, at least in part, through
opioid receptor-dependent mechanisms that may include changes in gene expression.